Biologic treatment or immunomodulation is not associated with postoperative anastomotic complications in abdominal surgery for Crohn's disease

References

• Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000;CD000067.
   PubMedGoogle Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541–9.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76.
   PubMed Web of Science ®Google Scholar
• Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005;54:237–41.
   PubMed Web of Science ®Google Scholar
• Jones DW, Finlayson SR. Trends in surgery for Crohn's disease in the era of infliximab. Ann Surg 2010;252:307–12.
   PubMed Web of Science ®Google Scholar
• Lazarev M, Ullman T, Schraut WH, Kip KE, Saul M, Regueiro M. Small bowel resection rates in Crohn's disease and the indication for surgery over time: experience from a large tertiary care center. Inflamm Bowel Dis 2010;16:830–5.
   PubMed Web of Science ®Google Scholar
• Schroll S, Sarlette A, Ahrens K, Manns MP, Goke M. Effects of azathioprine and its metabolites on repair mechanisms of the intestinal epithelium in vitro. Regul Pept 2005;131:1–11.
   PubMedGoogle Scholar
• Karukonda SR, Flynn TC, Boh EE, McBurney EI, Russo GG, Millikan LE. The effects of drugs on wound healing–part II. Specific classes of drugs and their effect on healing wounds. Int J Dermatol 2000;39:321–33.
   PubMed Web of Science ®Google Scholar
• Ljung T, Karlen P, Schmidt D, Hellstrom PM, Lapidus A, Janczewska I, Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849–53.
   PubMed Web of Science ®Google Scholar
• Appau KA, Fazio VW, Shen B, Church JM, Lashner B, Remzi F, Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg 2008;12:1738–44.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19–31.
   PubMed Web of Science ®Google Scholar
• Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg 2008;12:1730–6; discussion 1736–7.
   PubMed Web of Science ®Google Scholar
• Marchal L, D'Haens G, Van Assche G, Vermeire S, Noman M, Ferrante M, The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther 2004;19:749–54.
   PubMed Web of Science ®Google Scholar
• Mor IJ, Vogel JD, da Luz Moreira A, Shen B, Hammel J, Remzi FH. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 2008;51:1202–7; discussion 1207–10.
   PubMed Web of Science ®Google Scholar
• Nasir BS, Dozois EJ, Cima RR, Pemberton JH, Wolff BG, Sandborn WJ, Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease. J Gastrointest Surg 2010;14:1859–66.
   PubMed Web of Science ®Google Scholar
• Schluender SJ, Ippoliti A, Dubinsky M, Vasiliauskas EA, Papadakis KA, Mei L, Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum 2007;50:1747–53.
   PubMed Web of Science ®Google Scholar
• Selvasekar CR, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS, Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 2007;204:956–62; discussion 962–3.
   PubMed Web of Science ®Google Scholar
• Myrelid P, Olaison G, Sjodahl R, Nystrom PO, Almer S, Andersson P. Thiopurine therapy is associated with postoperative intra-abdominal septic complications in abdominal surgery for Crohn's disease. Dis Colon Rectum 2009;52:1387–94.
   PubMed Web of Science ®Google Scholar
• Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:2–6; discussion 16–19.
   PubMedGoogle Scholar
• Morson BS. Histopathology of Crohn's disease. Proc R Soc Med 1968;61:79–81.
   PubMedGoogle Scholar
• Yamamoto T, Allan RN, Keighley MR. Risk factors for intra-abdominal sepsis after surgery in Crohn's disease. Dis Colon Rectum 2000;43:1141–5.
   PubMed Web of Science ®Google Scholar
• Alves A, Panis Y, Bouhnik Y, Pocard M, Vicaut E, Valleur P. Risk factors for intra-abdominal septic complications after a first ileocecal resection for Crohn's disease: a multivariate analysis in 161 consecutive patients. Dis Colon Rectum 2007;50:331–6.
   PubMed Web of Science ®Google Scholar
• Post S, Betzler M, von Ditfurth B, Schurmann G, Kuppers P, Herfarth C. Risks of intestinal anastomoses in Crohn's disease. Ann Surg 1991;213:37–42.
   PubMed Web of Science ®Google Scholar
• Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003;125:320–7.
   PubMed Web of Science ®Google Scholar
• Bruewer M, Utech M, Rijcken EJ, Anthoni C, Laukoetter MG, Kersting S, Preoperative steroid administration: effect on morbidity among patients undergoing intestinal bowel resection for Crohns disease. World J Surg 2003;27:1306–10.
   PubMed Web of Science ®Google Scholar
• Fasth S, Hellberg R, Hulten L, Magnusson O. Early complications after surgical treatment for Crohn's disease with particular reference to factors affecting their development. Acta Chir Scand 1980;146:519–26.
   PubMedGoogle Scholar
• Schofield PF, Manson JM. Indications for and results of operation in inflammatory bowel disease. J R Soc Med 1986;79:593–5.
   PubMed Web of Science ®Google Scholar
• Golub R, Golub RW, Cantu R Jr, Stein HD. A multivariate analysis of factors contributing to leakage of intestinal anastomoses. J Am Coll Surg 1997;184:364–72.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Serious infections and mortality in association with therapies for Crohn's disease:TREAT registry. Clin Gastroenterol Hepatol 2006;4:621–30.
   PubMed Web of Science ®Google Scholar
• Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368–76.
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007;56:1754–64.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Early postoperative complications are not increased in patients with Crohn'sdisease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004;99:878–83.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Loftus EV Jr, Tremaine WJ, Pemberton JH, Harmsen WS, Schleck CD, Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis 2002;8:311–16.
   PubMed Web of Science ®Google Scholar
• Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007;46:645–60.
   PubMed Web of Science ®Google Scholar
• Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L, Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008;30:523–9.
   PubMed Web of Science ®Google Scholar